Lexicon Pharmaceuticals Inc expected to post a loss of 20 cents a share - Earnings Preview

Lexicon Pharmaceuticals

30/04/2024 22:37

* Lexicon Pharmaceuticals Inc  LXRX.OQ   LXRX.O  is expected
to show a rise in quarterly revenue when it reports  results on
May 2 for the period ending March 31 2024
    * The The Woodlands Texas-based  company is expected to
report a
5,736.5% increase in revenue to $1.401 million from $24 thousand
a year ago, according to the mean estimate from 4 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Lexicon Pharmaceuticals
Inc is
for a loss of 20 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 3.6%
in the last three months. ​
    * Wall Street's median 12-month price target for Lexicon
Pharmaceuticals Inc is $4.50​, above​ its last closing price
of $1.56. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.22       -0.22      -0.20     Beat    7.9
 Sep. 30 0001  -0.21       -0.21      -0.21     Met     2.2
 Jan. 1 0001   -0.17       -0.17      -0.22     Missed  -25.9​
 Mar. 31 2023  -0.18       -0.18      -0.17     Beat    5.2
 ​​Jan.        -0.14       -0.13                        -19.4
 1 0001                                                 
 Sep. 30 2022  -0.14       -0.14                        6.7​
 Jan. 1 0001   -0.16       -0.16      -0.16     Met     -1.7
 Jan. 1 0001   -0.17       -0.16      -0.16     Met     2.8
 This summary was machine generated April 30 at 21:37 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)